Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
![](https://cme.tarsusmedicaleducation.com/sites/default/files/styles/course_image_teaser/public/course/2024-05/1682%20Compendium%20052224_1200x630.jpg?itok=2Bud2pqa)
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events.
Category
- CMHC
Format
- Self-study / Enduring
Credits
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
![](https://cme.tarsusmedicaleducation.com/sites/default/files/styles/course_image_teaser/public/course/2024-06/Clinical%20Compendium%20%20-%20Understanding%20the%20Role%20of%20Lp%20060724_1200x630.jpg?itok=vZbhau0z)
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enha
Category
- CMHC
Format
- Self-study / Enduring
Credits
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation